Business
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in Electra Therapeutics, a late-stage US biotechnology company developing innovative treatments for immune-mediated diseases and cancer. Electra is advancing a new class of precision medicines designed to selectively target overactive immune cells that drive disease, while preserving normal immune function. This differentiated approach has the potential to deliver more effective and durable therapies for patients affected
About this update from Hbm Healthcare Investments Ag Temp
[{"type":"list","items":[{"val":[{"type":"text","content":"Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with serious immunological and cancer-related diseases","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Financing was co-led by EQT Life Sciences and Nextech, with participation from Sanofi, HBM Healthcare Investments, Mubadala Capital, and all existing investors","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"Proceeds will fund the registrational Phase 2/3 clinical study of the lead program in secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory disease with no approved therapies","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"Funding will also support expanding the lead program into hematologic cancers and establishing clinical proof-of-mechanism for a second program, with broad potential across immunology and inflammation","length":200,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":718,"olType":false},{"type":"text","content":"AMSTERDAM, Oct. 22, 2025 /PRNewswire/ -- EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in Electra Therapeutics, a late-stage US biotechnology company developing innovative treatments for immune-mediated diseases and cancer. Electra is advancing a new class of precision medicines designed to selectively target overactive immune cells that drive disease, while preserving normal immune function. This differentiated approach has the potential to deliver more effective and durable therapies for patients affected by serious immune-mediated and inflammatory conditions.","length":601,"tagName":"p"},{"type":"text","content":"The USD 183 million Series C will fund the global registrational Phase 2/3 clinical study of the lead program (ELA026) in secondary hemophagocytic lymphohistiocytosis (sHLH) and establish clinical proof-of-mechanism for Electra's second program (ELA822) that has broad potential across immunology. The round was co-led by EQT Life Sciences and Nextech, with participation from new investors Sanofi, HBM Healthcare Investments, and Mubadala Capital, alongside all existing investors.","length":486,"tagName":"p"},{"type":"text","content":"sHLH is a severe and life-threatening inflammatory condition triggered by underlying diseases such a...